Abstract: The present invention provides a novel salt of S-(?)-amlodipine, i.e., a nicotinic acid salt of S-(?)-amlodipine, a process for preparing the same, and a pharmaceutical composition comprising the same as an active ingredient.

Abstract: Provided is a process for the preparation of S-(?)-amlodipine from (R,S)-amlodipine in industrial-scale using L-(+)-tartaric acid, which is much cheaper than D-(?)-tartaric acid.

Abstract: The present invention relates to a processing method for preparing pharmacologically potent ginseng product and the extract therefrom which could provide abundant amount ginsenoside Rg5 showing various pharmacological activities with applying selected range of pressure and temperature into the method and therefore the composition comprising the processed ginseng and the extract thereof can be useful as a medicament or health care food in the prevention or treatment of various diseases, especially, cancer disease.

Abstract: The present invention provides a novel salt of S-(?)-amlodipine, i.e., a nicotinic acid salt of S-(?)-amlodipine, a process for preparing the same, and a pharmaceutical composition comprising the same as an active ingredient.

Abstract: Provided is a process for the preparation of S-(?)-amlodipine from (R,S)-amlodipine in industrial-scale using L-(+)-tartaric acid, which is much cheaper than D-(?)-tartaric acid.

Abstract: The present invention relates to a novel crystalline disodium pamidronate 3˜4 hydrate and a process for preparing it. More particularly, crystalline disodium pamidronate 3˜4 hydrate of the following formula I having the water content of 17.0˜20.0 wt % and being in the state of the mixture of trihydrate and tetrahydrate is prepared by neutralizing pamidronic acid with sodium compound, drying the formed disodium pamidronate, dissolving the disodium pamidronate in water, filtering sparingly soluble materials, allowing the filtrate to stand with stirring at normal temperature to form crystals, cooling and filtering the mixture to obtain crystals, and drying at the temperature of 75˜85° C. under normal pressure. The novel disodium pamidronate 3˜4 hydrate according to the present invention is much more stable compound structurally than the known disodium pamidronate pentahydrate.

Abstract: The present invention relates to a novel crystalline disodium pamidronate 3˜4hydrate and a process for preparing it. More particularly, crystalline disodium pamidronate 3˜4hydrate of the following formula I having the water content of 17.0˜20.0 wt % and being in the state of the mixture of trihydrate and tetrahydrate is prepared by neutralizing pamidronic acid with sodium compound, drying the formed disodium pamidronate, dissolving the disodium pamidronate in water, filtering sparingly soluble materials, allowing the filtrate to stand with stirring at normal temperature to form crystals, cooling and filtering the mixture to obtain crystals, and drying at the temperature of 75˜85° C. under normal pressure.

Abstract: Novel amine derivatives of the following general formula (I): ##STR1## (wherein) A may denote --(CH.sub.2)--O--, --(CH.sub.2).sub.2 --O--, or --(CH.sub.2).sub.2 --NH--;B may denote --(CH.sub.2).sub.2 --;R.sub.1 may denote a hydrogen atom, a halogen atom, a nitro group, a 1-pyrrolyl group, an acetamido group, an amino group or a dimethylamino group;R.sub.2 may denote a hydrogen atom or a nitro group;R.sub.3 and R.sub.4 may denote a hydrogen atom;R.sub.8a and R.sub.8b which are the same may denote a chlorine atom or a methoxy group;R.sub.9 may denote a hydrogen atom or an amino group;R may denote a methyl group; andX may denote a methanesulfonamido group, a 1-imidazolyl group or a nitro group or a salts thereof are useful as antiarrhythmic drugs.